Posted by Michael Wonder on 28 Sep 2017
NICE knocks-back Janssen's Imbruvica in Mantle cell lymphoma
28 September 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib).
In draft guidance NICE has declined to recommend Imbruvica’s use in England and Wales to treat mantle cell lymphoma.
The Institute said the drug’s use for this indication would not be a cost-effective use of NHS resources, despite Janssen having agreed to discount its price through a patient access scheme.
Imbruvica was previously available through the Cancer Drugs Fund (CDF) and NICE’s appraisal committee said they would consider any proposal from Janssen to include it in the new version of the CDF.
